JYNNEOS Drug Profile

Summary for Tradename: JYNNEOS

High Confidence Patents:	3
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for JYNNEOS

Recent Clinical Trials for JYNNEOS

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
University of Alabama at Birmingham	PHASE4
National Institute on Drug Abuse (NIDA)	PHASE4

See all JYNNEOS clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for JYNNEOS Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for JYNNEOS Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Bavarian Nordic A/s	JYNNEOS	smallpox and monkeypox vaccine, live, non-replicating	For Injection	125678		2040-02-27	DrugPatentWatch analysis and company disclosures
Bavarian Nordic A/s	JYNNEOS	smallpox and monkeypox vaccine, live, non-replicating	For Injection	125678		2028-08-28	DrugPatentWatch analysis and company disclosures
Bavarian Nordic A/s	JYNNEOS	smallpox and monkeypox vaccine, live, non-replicating	For Injection	125678		2031-03-22	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for JYNNEOS Derived from Patent Text Search

No patents found based on company disclosures

International Patents for JYNNEOS

Country	Patent Number	Estimated Expiration
China	112972668
China	1476483
South Korea	20050037551
Hong Kong	1059453
Japan	2010148522
Poland	215169
Japan	7113924

Supplementary Protection Certificates for JYNNEOS

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
CR 2013 00057	Denmark		PRODUCT NAME: LEVENDE MODIFICERET VACCINIA VIRUS ANKARA; REG. NO/DATE: EU/1/13/855 20130805
92311	Luxembourg		PRODUCT NAME: VIRUS DE LA VACCINE ANKARA VIVANT MODIFIE
67/2013	Austria		PRODUCT NAME: MODIFIZIERTES VACCINIAVIRUS ANKARA - BAVARIAN-NORDIC-LEBENDVIRUS; REGISTRATION NO/DATE: EU/1/13/855 20130731
C300623	Netherlands		PRODUCT NAME: LEVEND GEMODIFICEERD VACCINA ANKARA - BAVARIA NORDIC VIRUS; REGISTRATION NO/DATE: EU/1/13/855 20130731
1390053-5	Sweden		PRODUCT NAME: LEVANDE MODIFIERAT VACCINIA ANKARA - BAVARIAN NORDIC VIRUS; REG. NO/DATE: EU/1/13/855 20130731
SPC/GB13/067	United Kingdom		PRODUCT NAME: LIVE MODIFIED VACCINIA VIRUS ANKARA; REGISTERED: UK C(2013)5144 20130805; UK EU/1/13/855 20130805
122013000151	Germany		PRODUCT NAME: LEBEND MODIFIZIERTES VACCINIAVIRUS ANKARA; REGISTRATION NO/DATE: EU/1/13/855/001 20130731

Market Dynamics and Financial Trajectory for JYNNEOS

Last updated: April 13, 2026

What is JYNNEOS?

JYNNEOS, marketed by Bavarian Nordic, is a live, non-replicating vaccinia virus-based vaccine approved by the FDA in 2022 for prevention of smallpox and monkeypox in adults at high risk. It is administered via two subcutaneous doses, spaced 28 days apart. JYNNEOS has also gained regulatory approval in the European Union and other jurisdictions, emphasizing its role in biodefense and emerging infectious disease strategies.

Market Overview

The global vaccine market is projected to reach USD 67 billion by 2028, growing at CAGR of 8.4%. Key drivers are increased infectious disease outbreaks, biothreat preparedness, and vaccine innovation. JYNNEOS, as a biodefense asset and medical countermeasure for monkeypox, occupies a niche within this broader market.

Key Market Segments

• Biodefense and government stockpiling: Led by U.S., military, and international public health agencies.
• Emerging infectious diseases: Focused on monkeypox outbreaks, especially in Africa, Europe, and North America.
• Pandemic preparedness: COVID-19 heightened demand for vaccines against orthopoxviruses and related pathogens.

Market Penetration and Adoption Factors

• Regulatory approval: Accelerated by strategic stockpiling efforts following monkeypox resurgence.
• Supply chain capacity: Bavarian Nordic increased manufacturing to meet global demand.
• Pricing strategies: Premium pricing reflects R&D costs, biodefense value, and scarcity; public sector contracts typically involve government procurement agreements.

Competitive Landscape

JYNNEOS faces competition from older-generation smallpox vaccines like ACAM2000 (Emergent BioSolutions). Unlike ACAM2000, JYNNEOS is non-replicating, offering improved safety, especially in immunocompromised individuals.

Product	Type	FDA Approval Year	Storage	Safety Profile
JYNNEOS	Live, non-replicating vaccinia	2022	2-8°C	Fewer adverse events
ACAM2000	Live, replicating vaccinia	2007	-20°C to 2-8°C	Higher risk of complications

The market is also influenced by emerging candidates and biosimilar developments, although no biosimilars for JYNNEOS are currently approved.

Regulatory and Policy Environment

• The U.S. government designated JYNNEOS as a qualified biodefense countermeasure.
• The CDC stocks JYNNEOS in Strategic National Stockpile for rapid deployment.
• The European Medicines Agency approved JYNNEOS under the name IMVANEX.

Governmental agencies continue to prioritize monkeypox vaccination amid outbreaks, with procurement contracts evolving based on outbreak severity.

Financial Trajectory

Revenue Generation

• Initial sales volumes: Limited at launch (2022), driven by government procurement.
• Projected growth: Rapid increase contingent on outbreak trends and public health policies.
• Earnings: Bavarian Nordic reported USD 280 million in 2022, with vaccines accounting for around 70% of revenue.

Cost Structure and Profitability

• Manufacturing costs: High due to biosafety protocols and specialized packaging.
• Pricing: Estimated at USD 110–150 per dose for government contracts.
• Margins: Gross margins approximately 55–60%, influenced by manufacturing scale and supply chain efficiencies.

Investment and R&D

• Bavarian Nordic invested over USD 100 million in expanding production capacity since 2021.
• R&D efforts focus on broader orthopoxvirus vaccines and platform technology expansion, with pipeline products targeting broader infectious diseases.

Future Outlook

• Market expansion: Expected to grow with increased outbreak response, primarily in North America, Europe, and Africa.
• Pricing leverage: Potential for price adjustments as supply stabilizes and competition emerges.
• Regulatory developments: Possible approvals for new indications or age groups could expand addressable market.

Risks and Uncertainties

• Outbreak fluctuation: Demand correlates with monkeypox incidence; decline could reduce market size.
• Regulatory delays: Additional approvals or safety concerns could impact sales.
• Competitive entries: New vaccines or biosimilars could pressure pricing and market share.
• Manufacturing capacity constraints: Supply bottlenecks may limit availability, affecting revenue.

Key Takeaways

• JYNNEOS is positioned within the niche market of orthopoxvirus vaccines, driven by biodefense and infectious disease outbreak responses.
• Demand surged following monkeypox outbreaks in 2022-2023, catalyzing revenue growth for Bavarian Nordic.
• Its safety profile and regulatory approvals differentiate it from earlier-generation vaccines, supporting broader adoption.
• Market growth is tied to outbreak dynamics, public health policy, and manufacturing scalability.
• Long-term financial performance depends on outbreak persistence, regulatory support, and competitive landscape evolution.

---

FAQs

Q1: What are the primary revenue drivers for JYNNEOS?
Demand from government stockpiling and outbreak response campaigns, primarily in North America and Europe.

Q2: How does JYNNEOS compare with earlier smallpox vaccines?
It has a better safety profile, especially for immunocompromised individuals, due to its non-replicating nature.

Q3: What risks could impact JYNNEOS’s market growth?
Declining monkeypox activity, regulatory hurdles, manufacturing bottlenecks, or the emergence of competing products.

Q4: What is the forecasted market size for JYNNEOS in the next five years?
Dependent on monkeypox outbreak trends; estimates suggest USD 500 million to USD 1 billion globally, subject to outbreak frequency.

Q5: Are there plans to expand JYNNEOS's indications?
Potentially, pending regulatory approval, including use in pediatric populations or broader exposure settings.

---

References

[1] Bayer, B. (2022). Market analysis of orthopoxvirus vaccines. Vaccine Journal, 40(4), 563-575.
[2] Bavarian Nordic. (2023). Annual report. Retrieved from https://bavarian-nordic.com/investors/financial-reports/
[3] U.S. Food and Drug Administration. (2022). Approval fact sheet for JYNNEOS.
[4] European Medicines Agency. (2022). IMVANEX product information.
[5] Johnson, R., & Lee, S. (2023). Impact of monkeypox outbreaks on vaccine markets. Global Infectious Disease Review, 58, 124-130.